Adagene Inc (ADAG) Actualités

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

- Data reinforces mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Adagene to Present at Investor and Scientific Conferences in September

– Adagene’s CEO, Dr. Peter Luo, participating in SITC webinar on September 22 focused on essential role of Treg...

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

- Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 6-K &nb...

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

SAN DIEGO and SUZHOU, China, May 04, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 6-K &nb...

Annual and Transition Report (foreign Private Issuer) (20-f)

1595069850032009541350842.671.461.4854595667540657090001818838FY2022false10179 Huennekens Street Suite 103San...

Adagene Announces Updates to its Board of Directors

SAN DIEGO and SUZHOU, China, April 28, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 6-K &nb...

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

- Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 6-K &nb...

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

- Clinical data for wholly-owned anti-CTLA-4 franchise show best-in-class safety profiles for unmasked and...